NASDAQ:CGEN - Compugen Stock Price, Forecast & News

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CGEN stock has decreased by 39.3% and is now trading at $7.18. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Compugen.

Compugen is scheduled to release its next quarterly earnings announcement on Monday, May 18th 2020. View our earnings forecast for Compugen.

Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Thursday, February, 20th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. View Compugen's earnings history.

2 Wall Street analysts have issued 1-year price targets for Compugen's stock. Their forecasts range from $13.00 to $16.00. On average, they anticipate Compugen's stock price to reach $14.50 in the next year. This suggests a possible upside of 101.9% from the stock's current price. View analysts' price targets for Compugen.

News articles about CGEN stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Compugen earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutCompugen.

Some companies that are related to Compugen include Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Regenxbio (RGNX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), I-Mab (BDTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO) and Oyster Point Pharma (OYST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), Pluristem Therapeutics (PSTI), Sarepta Therapeutics (SRPT), Canopy Growth (CGC), Novavax (NVAX), AT&T (T), Catalyst Pharmaceuticals (CPRX), REDHILL BIOPHAR/S (RDHL) and Sorrento Therapeutics (SRNE).

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Compugen's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (17.50%), Nikko Asset Management Americas Inc. (15.89%), Renaissance Technologies LLC (1.42%), Taylor Frigon Capital Management LLC (1.41%), Rothschild Investment Corp IL (0.67%) and Defender Capital LLC. (0.59%).

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Benjamin F. Edwards & Company Inc., Jane Street Group LLC, UBS Group AG, Phoenix Holdings Ltd., and Raymond James & Associates.

CGEN stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., ARK Investment Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Oxford Asset Management LLP, ProShare Advisors LLC, and CWS Financial Advisors LLC.

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CGEN stock can currently be purchased for approximately $7.18.

Compugen has a market capitalization of $491.26 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe. View additional information about Compugen.

The official website for Compugen is http://www.cgen.com/.

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]